AI Article Synopsis
- The oligometastatic state in non-small cell lung cancer (NSCLC) is a recognized but poorly defined condition, leading to ongoing research into metastasis-directed therapy (MDT) using radiation.
- Several smaller randomized studies have indicated that radiation, particularly stereotactic body radiation therapy (SBRT), is both safe and effective for treating patients with oligometastatic NSCLC, paving the way for larger ongoing trials worldwide.
- Despite uncertainties regarding the definition and timing of radiation therapy, it remains a critical component of treatment for oligometastatic NSCLC, especially as systemic therapies continue to advance.
Article Abstract
Introduction: The oligometastatic state in non-small cell lung cancer (NSCLC) has recently become well-established. However, the specific definition of oligometastases remains unclear. Several smaller randomized studies have investigated the safety and efficacy of radiation as metastasis-directed therapy (MDT) in oligometastatic NSCLC, which have led the way to larger studies currently accruing patients globally.
Areas Covered: This review covers the definitions of 'oligometastases' and explains why the oligometastatic state is becoming increasingly relevant in metastatic NSCLC. This includes the rationale for MDT in oligometastatic NSCLC, specifically reviewing stereotactic body radiation therapy (SBRT) as a treatment strategy. This review details many randomized trials that support radiation as MDT and introduces trials that are currently accruing patients. Finally, it explores some of the controversies that warrant further investigation.
Expert Opinion: Radiation treatment, specifically SBRT, has been shown to be safe, convenient, and cost-effective as MDT. As systemic therapy, including targeted agents and immunotherapy, continues to improve, the precise role(s) and timing of radiation therapy may evolve. However, radiation therapy as MDT will continue to be an integral part of treatment in patients with oligometastatic NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17476348.2023.2284362 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications.
JTO Clin Res Rep
December 2024
Department of Pulmonary Diseases, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands.
This review discusses the current data on predictive and prognostic biomarkers in oligometastatic NSCLC and discusses whether biomarkers identified in other stages and widespread metastatic disease can be extrapolated to the oligometastatic disease (OMD) setting. Research is underway to explore the prognostic and predictive value of biological attributes of tumor tissue, circulating cells, the tumor microenvironment, and imaging findings as biomarkers of oligometastatic NSCLC. Biomarkers that help define true OMD and predict outcomes are needed for patient selection for oligometastatic treatment, and to avoid futile treatments in patients that will not benefit from locoregional treatment.
View Article and Find Full Text PDFEmergence of Circulating Tumor DNA as a Precision Biomarker in Lung Cancer Radiation Oncology and Beyond.
Hematol Oncol Clin North Am
December 2024
Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Electronic address:
Circulating tumor DNA (ctDNA) is emerging as a transformative biomarker in the management of non-small cell lung cancer (NSCLC). This review focuses on its role in detecting minimal residual disease (MRD), predicting treatment response, and guiding therapeutic decision-making in radiation oncology and immunotherapy. Key studies demonstrate ctDNA's prognostic value, particularly in identifying relapse risk and refining patient stratification for curative-intent and consolidative treatments.
View Article and Find Full Text PDFThe Role of Stereotactic Body Radiotherapy in Oligometastatic Non-Small Cell Lung Cancer.
Curr Oncol
December 2024
Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.
Non-small cell lung cancer (NSCLC) is a major cause of mortality in Canada, with many patients presenting with metastatic disease. The oligometastatic state (OM-NSCLC) may be amenable to cure using aggressive local consolidative therapies. Stereotactic body radiotherapy (SBRT), which entails the utilization of a high dose of radiation in one or few fractions, has many benefits in this setting, including its applicability in varied patient populations to ablate lesions in varied anatomical locations.
View Article and Find Full Text PDFLong-term outcomes of surgical treatment of non-small cell lung cancer with oligometastatic disease involving only the brain in the era of PET/CT.
J Cardiothorac Surg
December 2024
Department of General Thoracic Surgery, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Background: The prognosis of patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) has been improving owing to advancements in imaging techniques and new treatment approaches such as tyrosine kinase inhibitors. This study aimed to investigate the long-term outcomes, including the clinical course after recurrence, of patients with synchronous oligometastatic NSCLC with only brain metastases, treated with bifocal treatment.
Methods: We retrospectively analyzed 22 patients with clinical T1-4 and N0-1 NSCLC with synchronous brain metastases who were diagnosed by preoperative PET/CT and brain CT or MRI and underwent pulmonary resection for the primary site and surgery or radiation therapy for brain metastases at our institution from 2005 to 2019.
Successful Treatment With Lorlatinib Monotherapy for Secondary Central Nervous System Oligometastatic Disease in Refractory Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer.
Cureus
November 2024
Hematology and Medical Oncology, Tripler Army Medical Center, Honolulu, USA.
The anaplastic lymphoma kinase (ALK) gene plays crucial roles in both normal brain development and oncogenesis, particularly in non-small cell lung cancer (NSCLC). Metastatic ALK-positive NSCLC is characterized by ALK tyrosine kinase domain rearrangements, prompting the use of ALK tyrosine kinase inhibitors (TKIs) to target the mutation. While first-line treatment options include alectinib, brigatinib, and lorlatinib per National Comprehensive Cancer Network (NCCN) guidelines, therapeutic challenges arise in cases of disease progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!